Current treatments in diabetic macular oedema: systematic review and meta-analysis

Abstract

ObjectivesThe aim of this systematic review is to appraise the evidence for the use of anti-VEGF drugs and steroids in diabetic macular oedema (DMO) as assessed by change in best corrected visual acuity (BCVA), central macular thickness and adverse eventsData sourceMEDLINE, EMBASE, Web of Science with Conference Proceedings and the Cochrane Library (inception to July 2012). Certain conference abstracts and drug regulatory web sites were also searched.Study eligibility criteria, participants and interventionsRandomised controlled trials were used to assess clinical effectiveness and observational trials were used for safety. Trials which assessed triamcinolone, dexamethasone, fluocinolone, bevacizumab, ranibizumab, pegaptanib or aflibercept in patients with DMO were included.Study appraisal and synthesis methodsRisk of bias was assessed using the Cochrane risk of bias tool. Study results are narratively described and, where appropriate, data were pooled using random effects meta-analysis.ResultsAnti-VEGF drugs are effective compared to both laser and placebo and seem to be more effective than steroids in improving BCVA. They have been shown to be safe in the short term but require frequent injections. Studies assessing steroids (triamcinolone, dexamethasone and fluocinolone) have reported mixed results when compared with laser or placebo. Steroids have been associated with increased incidence of cataracts and intraocular pressure rise but require fewer injections, especially when steroid implants are used.LimitationsThe quality of included studies varied considerably. Five of 14 meta-analyses had moderate or high statistical heterogeneity.Conclusions and implications of key findingsThe anti-VEGFs ranibizumab and bevacizumab have consistently shown good clinical effectiveness without major unwanted side effects. Steroid results have been mixed and are usually associated with cataract formation and intraocular pressure increase. Despite the current wider spectrum of treatments for DMO, only a small proportion of patients recover good vision (≥20/40), and thus the search for new therapies needs to continue.

Endothelial Protein C–Targeting Liposomes Show Enhanced Uptake and Improved Therapeutic Efficacy in Human Retinal Endothelial Cells

“…[40][41][42][43] These findings have led to the emergence of several novel treatment modalities based on the administration of antivascular endothelial growth factor agents and corticosteroids to the diseased retina. 44,45 Corticosteroids are an attractive option due to their broad range of actions including anti-inflammatory and antiangiogenic effects. [46][47][48][49] Corticosteroid-loaded liposomes have been reported for several decades, but drug loading efficacy and release rates have presented significant challenges.…”

Modern approach to early diagnosis and pathogenetic treatment of diabetic retinopathy

“…В течение многих лет во всем мире идет поиск новых эффективных фармакологических методов лечения ДР на доклинической стадии (ДР0) и ран-ней стадии (ДРI) [1][2][3]. Наиболее часто применяе-мыми препаратами являются ангиопротекторы и антиоксиданты [4], метаболические и антиишеми-ческие препараты [5], ингибиторы ангиотензин-превращающего фермента [5], фибраты [6], антоци-анозиды черники, ферментные препараты при мас-сивных кровоизлияних в сетчатку и др.…”

Update on the Management of Diabetic Macular Edema

“…Despite ample research and large meta-analyses demonstrating little systemic risk with anti-VEGF treatments in most patients, [23][24][25][26][27] clinicians should be mindful of these agents in this higher-risk population. A recent meta-analysis looking specifically at diabetic patients with intensive (monthly for 2 years) intravitreal anti-VEGF injections found an increased risk of death and potentially cerebrovascular accidents, although not myocardial infarction or arteriothrombotic events, in this high-risk group.…”